Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan
Authors:
- Saltanat TuganbekovaSTSaltanat Tuganbekova
- Kairat KabulbayevKKKairat Kabulbayev
- Duman TurebekovDTDuman Turebekov
- Sholpan KanafinaSKSholpan Kanafina
- Galiya ShaimardanovaGSGaliya Shaimardanova
- Olimkhon SharapovOSOlimkhon Sharapov
- Fariz BabayevFBFariz Babayev
- Miranda TsilosaniMTMiranda Tsilosani
- Kirill KomissarovKKKirill Komissarov
- 6 September 2025
- journal article
- Published by Australasia Publishing Group in Central Asian Journal of Nephrology
- Vol. 1 (1) , cajn005
Abstract
The advent of targeted complement inhibitors represents a paradigm shift in managing complement-mediated nephropathies. Integrating these therapies into healthcare systems, particularly in resource-variable settings, requires strategic planning. A national council of experts was convened in October 2024 with the purpose of obtaining a clinical expert opinion to develop practical recommendations for improving the organization and optimization of medical care for patients with C3 glomerulopathy (C3G) and IgA nephropathy (IgAN) in Kazakhstan. The council identified critical systemic gaps, including inconsistent use of renal biopsy, lack of specialized nephropathology, absence of treatment algorithms, and fragmented patient care. A consensus was reached on key recommendations for a new national clinical protocol. These include mandating pathological confirmation, creating detailed treatment and monitoring algorithms, establishing a national registry and coordination center, and investing in specialized training for healthcare professionals. The systematic framework proposed by the council provides an actionable roadmap to overcome barriers to care. This model ensures equitable patient access to novel therapies and may serve as a blueprint for other nations navigating the integration of advanced treatments into clinical practice.Keywords
This publication has 5 references indexed in Scilit:
- Beautiful and effective: what art can do for nephrologists and for our patientsNephrology Dialysis Transplantation, 2023
- Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G TrialKidney International Reports, 2022
- KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular DiseasesKidney International, 2021
- C3 glomerulopathy — understanding a rare complement-driven renal diseaseNature Reviews Nephrology, 2019
- An update on the pathogenesis and treatment of IgA nephropathyKidney International, 2012